Integrative analysis reveals luteolin’s molecular targets and mechanisms in pancreatic cancer treatment
This study identifies MET as a critical therapeutic target of luteolin in pancreatic cancer, providing mechanistic insights into luteolin's anti-cancer effects via the MET/PI3K/AKT signaling pathway and supporting its potential clinical application.
Authors
- Lili Chen (ORCID: https://orcid.org/0009-0002-1016-0465)
- Danhong Pan
- Peixi Zhong
- Shixia Li
- Binbo Fang
- Yifu Feng
Institutions
- Taizhou Central Hospital (CN)
- The First People's Hospital of Wenling (CN)
- Taizhou University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1186/s40001-026-04056-x
- Primary Topic
- FOXO transcription factor regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00